| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,000,000 |
| Market
Cap: |
1.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1151 - $0.1151 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ReShape Lifesciences is a weight-loss solutions company, providing a portfolio of products and services that manage and treat obesity and associated metabolic disease. Co.'s primary operations are in the following geographical areas: U.S., Australia and certain European and Middle Eastern countries. Co.'s portfolio includes the Lap-Band Adjustable Gastric Banding System, the reshapecare virtual health coaching program, the ReShape Marketplace, the Obalon Balloon System, the ReShape Vest, an investigational device to help treat more patients with obesity, and the Diabetes Bloc-Stim Neuromodulation device, a technology under development as a new treatment for type 2 diabetes mellitus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,702 |
37,702 |
| Total Buy Value |
$0 |
$0 |
$26,907 |
$45,329 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
639 |
443,150 |
| Total Sell Value |
$0 |
$0 |
$777 |
$106,051 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
7 |
23 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Kelly |
Chief Operating Officer |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
65,000 |
|
- |
|
| Hussainy Nooshin |
VP of Finance |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,875 |
21,875 |
|
- |
|
| Drake Neil |
VP Research and Development |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
17,938 |
17,938 |
|
- |
|
| Plovanic William J. |
Chief Financial Officer |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
45,000 |
|
- |
|
| Vandenberg Amy |
VP of Reg. and Clin. Affairs |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
75,000 |
|
- |
|
| Young Donald R |
VP of Quality Assurance |
• – – |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,377 |
20,377 |
|
- |
|
| Rasdal Andrew P |
President & CEO |
• • – |
2018-04-30 |
4 |
A |
$3.27 |
$9,767 |
D/D |
2,987 |
457,058 |
|
- |
|
| Drake Neil |
VP Research and Development |
• – – |
2018-04-30 |
4 |
A |
$3.27 |
$8,970 |
D/D |
2,743 |
29,593 |
|
- |
|
| Brister Mark |
Chief Technology Officer |
• – – |
2018-04-30 |
4 |
A |
$3.27 |
$8,574 |
D/D |
2,622 |
166,492 |
|
- |
|
| Drake Neil |
VP Research and Development |
• – – |
2018-03-15 |
4 |
B |
$3.96 |
$19,778 |
D/D |
5,000 |
26,850 |
0.01 |
- |
|
| Plovanic William J. |
Chief Financial Officer |
• – – |
2018-03-14 |
4 |
B |
$4.04 |
$43,229 |
I/I |
10,712 |
15,000 |
0.01 |
- |
|
| Plovanic William J. |
Chief Financial Officer |
• – – |
2018-03-13 |
4 |
B |
$4.05 |
$78,101 |
I/I |
19,288 |
9,588 |
0.01 |
- |
|
| Drake Neil |
VP Research and Development |
• – – |
2018-02-02 |
4 |
OE |
$0.76 |
$21,211 |
D/D |
13,926 |
21,850 |
|
- |
|
| Vandenberg Amy |
VP of Reg. and Clin. Affairs |
• – – |
2018-01-29 |
4 |
OE |
$0.87 |
$6,464 |
D/D |
6,650 |
6,650 |
|
- |
|
| Vandenberg Amy |
VP of Reg. and Clin. Affairs |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
|
- |
|
| Brister Mark |
Chief Technology Officer |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
65,000 |
|
- |
|
| Brister Mark |
Chief Technology Officer |
• – – |
2017-10-31 |
4 |
A |
$7.17 |
$13,336 |
D/D |
1,860 |
163,870 |
|
- |
|
| Johnson Steven Ernest |
VP of Operations |
• – – |
2017-10-31 |
4 |
A |
$7.17 |
$6,754 |
D/D |
942 |
1,689 |
|
- |
|
| Drake Neil |
VP Research and Development |
• – – |
2017-10-31 |
4 |
A |
$7.17 |
$12,497 |
D/D |
1,743 |
7,924 |
|
- |
|
| Hussainy Nooshin |
VP of Finance |
• – – |
2017-10-31 |
4 |
A |
$7.17 |
$3,599 |
D/D |
502 |
58,545 |
|
- |
|
| Rasdal Andrew P |
President & CEO |
• • – |
2017-10-31 |
4 |
A |
$7.17 |
$5,793 |
D/D |
808 |
454,071 |
|
- |
|
| Rasdal Andrew P |
President & CEO |
• • – |
2017-04-30 |
4 |
A |
$9.03 |
$24,995 |
D/D |
2,768 |
453,263 |
|
- |
|
| Drake Neil |
|
– • – |
2017-04-30 |
4 |
A |
$9.03 |
$14,999 |
D/D |
1,661 |
6,181 |
|
- |
|
| Young Donald R |
VP of Quality Assurance |
• – – |
2017-04-30 |
4 |
A |
$9.03 |
$16,868 |
D/D |
1,868 |
1,868 |
|
- |
|
| Morisey Erin |
VP Strategic Partnerships |
• – – |
2017-04-30 |
4 |
A |
$9.03 |
$16,119 |
D/D |
1,785 |
1,785 |
|
- |
|
139 Records found
|
|
Page 5 of 6 |
|
|
